Skip to main content
Premium Trial:

Request an Annual Quote

Gerrit van den Dool, Erik Walldén, , Peter Buhl Jensen, Gillies O’Bryan-Tear, Bob Boyne

Gerrit van den Dool has been promoted to vice president of sales at Sigma-Aldrich while David Smoller was promoted to president of the research biotech business unit, the company said this week.
Van den Dool had been head of the company’s European research sales since 1999. Before that he was at Amersham-Pharmacia and Molecular Dynamics. In his new position, which was newly created, he will be responsible for sales for all three of Sigma-Aldrich’s research business units.
Smoller had been the company’s vice president of R&D since 2004. He is the founder of Genome Systems and ProteoPlex.
The company also said that Gilles Cottier, president of the research essentials business unit and a member of the company’s executive management group, will add direct oversight of operations in China and India to his existing responsibilities.

Erik Walldén was appointed CEO of Affibody, the company announced this week. The appointment becomes effective July 15. He had been president and CEO of Biacore. He was also the former CEO of Pyrosequencing. He replaces Ulf Boberg who will become senior vice president of clinical development and business development at Affibody.
Affibody also announced this week the election of two new members to its board, Peter Buhl Jensen, and Gillies O’Bryan-Tear.
Jensen is CEO and co-founder of TopoTarget. Bryan-Tear is a consultant and was previously vice president of global clinical R&D at GlaxoSmithKline Biologicals.

Syngene last week said Bob Boyne has joined the company as US sales manager. Boyne had been a regional sales manager at Fujifilm Life Sciences Imaging Group for seven years. Before that he was marketing equipment for scientific applications at Fujifilm.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.